Cytophage Technologies Ltd.

OTCPK:CPTC.F Stock Report

Market Cap: US$9.7m

Cytophage Technologies Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Steven Theriault

Chief executive officer

CA$350.0k

Total compensation

CEO salary percentage100.0%
CEO tenureless than a year
CEO ownership9.3%
Management average tenureno data
Board average tenureless than a year

Recent management updates

No updates

Recent updates

No updates

CEO Compensation Analysis

How has Steven Theriault's remuneration changed compared to Cytophage Technologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CA$8m

Mar 31 2024n/an/a

-CA$8m

Dec 31 2023CA$350kCA$350k

-CA$5m

Dec 31 2022CA$350kCA$350k

-CA$4m

Compensation vs Market: Steven's total compensation ($USD250.93K) is below average for companies of similar size in the US market ($USD648.89K).

Compensation vs Earnings: Steven's compensation has been consistent with company performance over the past year.


CEO

Steven Theriault

less than a year

Tenure

CA$350,000

Compensation

Dr. Steven Theriault, B.Sc., M.Sc., Ph D., is Chief Executive Officer, Chief Science Officer & Director of Cuspis Capital III Ltd. (formerly known as Cytophage Technologies Inc.) Dr. Steven Theriault is a...


Board Members

NamePositionTenureCompensationOwnership
Steven Theriault
CEO, Chief Science Officer & Directorless than a yearCA$350.00k9.27%
$ 896.2k
Michael Cochrane
Independent Directorless than a yearno datano data
John Snisarenko
Independent Directorless than a yearno datano data
Harold Wolkin
Independent Directorless than a yearno data1.11%
$ 107.4k
William Ollerhead
Director5.2yrsno data0.90%
$ 86.5k
Robert Gabor
Independent Directorless than a yearno data0.19%
$ 17.9k
Shantha Kodihalli
Independent Directorless than a yearno data0.074%
$ 7.2k
Michael Sorkin
Directorless than a yearno datano data

0.8yrs

Average Tenure

61yo

Average Age

Experienced Board: CPTC.F's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.